Last reviewed · How we verify
Pain Cocktail with Exparel
Pain Cocktail with Exparel is a marketed product by DeClaire LaMacchia Orthopaedic Institute, leveraging Exparel's extended-release liposomal bupivacaine for pain management. The key strength lies in its unique mechanism of action, which provides prolonged local anesthesia, differentiating it from traditional pain management options. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Pain Cocktail with Exparel |
|---|---|
| Also known as | liposomal bupivacaine |
| Sponsor | DeClaire LaMacchia Orthopaedic Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multimodal Pain Management Following Primary TKA (EARLY_PHASE1)
- Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management (PHASE2)
- Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel (PHASE4)
- Effectiveness of Intraoperative Exparel for Postoperative Pain Control in Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pain Cocktail with Exparel CI brief — competitive landscape report
- Pain Cocktail with Exparel updates RSS · CI watch RSS
- DeClaire LaMacchia Orthopaedic Institute portfolio CI